Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC23 Cilostazol
D01896 Cilostazol (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Platelet Modifying Agents
Platelet Modifying Agents, Other
Cilostazol
D01896 Cilostazol (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D01896 Cilostazol (JP18/USP/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01507 Phosphodiesterase III inhibitor
D01896 Cilostazol
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
D01896 Cilostazol
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D01896 Cilostazol
DG01644 CYP2D6 substrate
D01896 Cilostazol
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D01896 Cilostazol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Thromboxane
TBXA2R
D01896 Cilostazol (JP18/USP/INN) <JP/US>
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE3
D01896 Cilostazol (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01896 Cilostazol
D01896 Cilostazol tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01896
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01896
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01896